1 week Ago By ABMN Staff
JMP Securities restated their market outperform rating on shares of Vor Biopharma ( NYSE:VOR – Free Report ) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $12.00 price objective on the stock.
Several other brokerages have also weighed in on VOR. Barclays cut their price objective on shares of Vor Biopharma from $10.00 to $3.
00 and set an overweight rating on the stock in a report on Wednesday, August 14th. Wedbush reissued an outperform rating and set a $11.00 price objective on shares of Vor Biopharma in a research note on Friday, May 10th.
HC Wainwright reaffirmed a buy rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Friday. Finally, Oppenheimer reissued an outperform rating and set a $10.
00 price target (down previously from $15.00) on shares of Vor Biopharma in a research report on Monday, May 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.
com, the company has an average rating of Buy and a consensus target price of $10.92. Get Our Latest Research Report on VOR Vor Biopharma Trading Up 10.
1 % Vor Biopharma ( NYSE:VOR – Get Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.
41). As a group, equities research analysts forecast that Vor Biopharma will post -1.51 EPS for the current fiscal year.
Hedge Funds Weigh In On Vor Biopharma Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Vor Biopharma by 4.
0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after buying an additional 69,436 shares during the last quarter.
Acadian Asset Management LLC acquired a new position in Vor Biopharma during the 1st quarter worth $126,000. Renaissance Technologies LLC grew its stake in shares of Vor Biopharma by 48.0% in the second quarter.
Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Vor Biopharma by 177.0% during the second quarter.
Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Vor Biopharma during the second quarter valued at about $53,000. 97.
29% of the stock is owned by institutional investors. Vor Biopharma Company Profile ( Get Free Report ) Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Featured Stories Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter ..
